

A Rapid Lysostaphin Production Approach and a Convenient Novel Lysostaphin Loaded Nano-emulgel; As a

Mohamed Ahmed Emad El Gendy ,Hanzada T Nour El-Din, Noha M Elhosseiny,
Azza A Mahmoud, Manal MM Hussein, Ahmed S Attia

Abstract

almost every organ in the human body. Alarmingly, the rapid emergence of options. Herein, we propose sustainable, low-cost production of recombinant lysostaphin (rLST), which is a native bacteriocin destroying the staphylococcal cell y cmm"vj tqwi j "kvu"gp fqrgrvkfcug"cevkxkv{0" Yg"eq o dkgpf"vjg"wug"qh"G0" eqnk"DN21(DE3)/pET15b, factorial design, and simple Ni-NTA affinity chromatography to optimize rLST production. The enzyme yield was up to 50 mg/L culture, surpassing reported systems. Our rLST demonstrated superlative biofilm combating ability by inhibiting staphylococcal biofilms formation and detachment of already formed biofilms, compared to vancomycin and linezolid. Furthermore, we aimed at developing a novel rLST topical formula targeting staphylococcal skin infections. The phase inversion composition (PIC) method fulfilled this aim with its simple preparatory steps and affordable components. LST nano-emulgel (LNEG) was able to extend active LST release up to 8 h and cure skin infections in a murine skin model. We are introducing a rapid, convenient rLST production platform with an outcome of pure, active rLST incorporated into an effective LNEG formula with scaling-up potential to satisfy the needs of both research and therapeutic purposes

Biomolecules 2020, March